SFM
INDP icon

Sphera Funds Management’s Indaptus Therapeutics INDP Stock Holding History

Sphera Funds Management’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-277
Closed -$2.69M – 90
2019
Q2 		$2.69M Buy
+277
New +$3.49M 0.37% 65

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Sphera Funds Management's INDP Position: Q3 2019 in Review

Sphera Funds Management sold out of Indaptus Therapeutics (INDP) in Q3 2019, closing a stake of 277 shares — an estimated $2.69M sold.

Sphera Funds Management first reported a position in INDP in Q2 2019 and held it in 1 quarter. The position peaked at $2.69M in Q2 2019. 33 funds tracked by Wall St. Rank hold INDP as of Q3 2019.

  • Sphera Funds Management reported no remaining Indaptus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Sphera Funds Management sold 277 Indaptus Therapeutics shares in Q3 2019, an estimated $2.69M.
  • Sphera Funds Management first reported a position in Indaptus Therapeutics in Q2 2019 and held it in 1 quarter.
  • Sphera Funds Management's Indaptus Therapeutics position peaked at $2.69M in Q2 2019.
  • 33 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2019.

Based on Sphera Funds Management's 13F filing for Q3 2019, filed 14 Nov 2019.